Global Lung Cancer Drugs Market Report 2021 - Opportunities And Strategies, Market Forecast And Trends

16 Sep, 2021

The lung cancer drugs market consists of sales of lung cancer drugs. Lung cancer is a type of cancer that decreases the ability of lungs to supply oxygen to the bloodstream because of uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy and targeted therapy. On the basis of the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

Global Lung Cancer Drugs Market Size And Drivers:

The global lung cancer drugs market is expected to grow from $8.06 billion in 2020 to $8.67 billion in 2021 at a compound annual growth rate (CAGR) of 7.6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $12.84 billion in 2025 at a CAGR of 10.3%. The growing demand for global lung cancer drugs to meet the needs of the rising prevalence rate of lung cancer is expected to drive the market.

Request For A Sample For The Global Lung Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2567&type=smp

Trends In The Global Lung Cancer Drugs Market

Targeted drug therapy in combination with other therapies is an emerging trend in the lung cancer market. It involves the use of immunotherapy drugs combined with other therapies such as chemotherapy that help in early diagnosis, prevention and treatment of the disease. In this regard, drug manufacturers are developing targeted drug therapies for better diagnosis and treatment of lung cancer. For example, in 2018, Merck and Co. developed pembrolizumab, which is a drug that helps the immune system to detect and fight cancer cells when used in addition to chemotherapy. This combination therapy showed an improvement in lung cancer status in patients. The drug is a major product of Merck and Co., and is sold under the brand name Keytruda.

Global Lung Cancer Drugs Market Segments:
The global lung cancer drugs market is further segmented –
By Disease Type: Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC)
By End User: Hospitals, Clinics, Others
By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Others
By Geography: The global lung cancer drugs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Lung Cancer Drugs Market At:

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Lung Cancer Drugs Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides lung cancer drugs market overviews, analyzes and forecasts market size and growth for the global lung cancer drugs market, lung cancer drugs market share, lung cancer drugs market players, lung cancer drugs market segments and geographies, lung cancer drugs market’s leading competitors’ revenues, profiles and market shares. The lung cancer drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)